Though Sun Pharma may post good June quarter earnings, the quality of earnings may suffer, particularly the topline growth, said Surajit Pal of Prabhudas Lilladher. In an interview to CNCB-TV18, Pal said commentary on the company's Halol Plant will be closely watched. Talking on Glenmark earnings estimates, he said real growth would come in Q2 of FY17 and expects operating margin to be around 19.8 percent. Further, total US sales may likely growth to USD 98-100 million this quarter, he said. Meanwhile, his top picks in the sector are Aurobindo Pharma , Jubilant Life Sciences and Glenmark Pharma.
0 comments:
Post a Comment